Mentions
Extended reach
Total likes
Video views
AI synopsis
Several discussions highlight the promising yet cautious nature of the study, with references to specific results such as the reduction of inflammatory markers and the need for repeated dosing in critically ill patients. The tone varies from clinical curiosity to skepticism, with phrases like 'hard to interpret this data' and 'seems at least as good as...' illustrating the ongoing debate about the treatment's real-world effectiveness.
Discussions show mixed opinions about the article's findings, with some emphasizing the potential of tocilizumab and others questioning its effectiveness. There is no clear consensus supporting or opposing the publication.
Many posts express curiosity by referencing specific data points like IL-6 levels and mentioning ongoing trials or multiple studies. The discussion reflects a moderate level of engagement with the research details.
The discussions include references to multiple studies, clinical observations, and methodological considerations, indicating active engagement, though mostly at a surface level.
Participants recognize the research's significance in the context of COVID-19 treatment options, but noting limitations like small sample sizes and lack of controls reduces the perception of high impact.
Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tell me what you make of this... It seems at least as good as the non-peer reviewed abstract that got us all jumping off the IL-6 cliff...
Tocilizumab treatment in #COVID19: a single center experience 15 patients - 13 very ill - 8/15 received steroids too - inflammatory markers improved - some got single dose Toci It is very hard to interpret this data https://t.co/Q9TxREryK8 https://t.co/GC5onap1pN
Several other reports that the effectiveness of this drug is best as the cytokines storm begins with increasing oxygen requirements -#Tocilizumab treatment in COVID‐19: A single center experience - Luo - - Journal of Medical Virology - Wiley Online Library https://t.co/6qTK3UQ9qA
Tocilizumab treatment in COVID‐19: a single center experience - Luo - - Journal of Medical Virology - Wiley Online Library https://t.co/5T3wlnEEBp
Another small cohort study of #tocilizumab (TCZ) for #COVID19 (n=15). Results look favourable, but no control group. Authors recommend repeated dose for critically ill patients with elevated IL‐6. https://t.co/LyAV3X85f1
tocilizumab certains espoirs thérapeutiques ont été placé dans cet inhibiteur monoclonal de l’IL6 avec des résultats relativement encourageants quant au potentiel thérapeutique https://t.co/u4G5fQs3mz https://t.co/WkLX9K0LmR https://t.co/onSwV16qq5
Continuing with our discussion on COVID19 medications, this video explains how drugs like Tocilizumab, Favipiravir, and others act to combat lung damage and breathlessness. We analyze their effectiveness, clinical…
This video explores cytokine storm syndrome, its impact on COVID-19 patients, and discusses Tocilizumab treatment outcomes, highlighting effectiveness in managing high IL6 levels and the importance of personalized…
RT @CetiCov: tocilizumab certains espoirs thérapeutiques ont été placé dans cet inhibiteur monoclonal de l’IL6 avec des résultats relative…
RT @CetiCov: tocilizumab certains espoirs thérapeutiques ont été placé dans cet inhibiteur monoclonal de l’IL6 avec des résultats relative…
RT @CetiCov: tocilizumab certains espoirs thérapeutiques ont été placé dans cet inhibiteur monoclonal de l’IL6 avec des résultats relative…
RT @CetiCov: tocilizumab certains espoirs thérapeutiques ont été placé dans cet inhibiteur monoclonal de l’IL6 avec des résultats relative…
RT @CetiCov: tocilizumab certains espoirs thérapeutiques ont été placé dans cet inhibiteur monoclonal de l’IL6 avec des résultats relative…
RT @CetiCov: tocilizumab certains espoirs thérapeutiques ont été placé dans cet inhibiteur monoclonal de l’IL6 avec des résultats relative…
tocilizumab certains espoirs thérapeutiques ont été placé dans cet inhibiteur monoclonal de l’IL6 avec des résultats relativement encourageants quant au potentiel thérapeutique https://t.co/u4G5fQs3mz https://t.co/WkLX9K0LmR https://t.co/onSwV16qq5
4-6-2020: China has 2 pro-Actemra meta-analyses (Jie Zhao, Meng Zhao) and 4 pro-Actemra studies (Jianbo Tian, Xiaoling Xu, Jia Zeng, Kai-Lian Zheng). I made Pan Luo my 5th head researcher of Chinese pro-Actemra studies, he's the world's 70th on my list: https://t.co/MVQaTYVILb
RT @drsubramanians: #tocilizumab is being tried in critically ill patients with #covid_19 15 patients with severe #covid19 & ⬆️ #IL6 lev…
RT @hichachu: https://t.co/2sK29YJPpr TCZは、COVID-19患者の炎症活動を緩和するのに役立つ。 重症のCOVID-19患者には、TCZの反復投与が推奨される。 TCZの影響をさらに検証するには、さらにケースが必要。
RT @hichachu: https://t.co/2sK29YJPpr TCZは、COVID-19患者の炎症活動を緩和するのに役立つ。 重症のCOVID-19患者には、TCZの反復投与が推奨される。 TCZの影響をさらに検証するには、さらにケースが必要。
https://t.co/2sK29YJPpr TCZは、COVID-19患者の炎症活動を緩和するのに役立つ。 重症のCOVID-19患者には、TCZの反復投与が推奨される。 TCZの影響をさらに検証するには、さらにケースが必要。
@abbasmaj This drug is globally used to manage leukotrienes storms in all critically ill patients of COVID 19. A COMMENDABLE AND BOLD STEP. Early View RESEARCH ARTICLE Free Access Tocilizumab treatment in COVID‐19: A single center experience
https://t.co/cwwKEUESKO
@Sulci_Gyri https://t.co/yhBOYTG3sP Maybe you will find this helpful.
Tocilizumab treatment in COVID‐19: A single center experience https://t.co/WHqua9cAmd
@karimero77 @b_t_n_s_ Lou P, et. al. Tocilizumab treatment in COVID-19: A single center experience. J Med Virol. 2020;1-5
Tocilizumab treatment in COVID‐19: A single center experience https://t.co/xhXMLj8I1G
@stokofano @Noahpinion https://t.co/UeTpSJWlEa
RT @Metallaw666: この論文見てると、トシリズマブで解決はするわけではないかなと。 さっきのリツイを考慮すると、高血圧がハイリスクなのは確かにと思ってしまうね。 https://t.co/f24ZCJ2cYR
Tocilizumab treatment in COVID‐19: A single center experience https://t.co/N5S4TfgXEV
Tocilizumab treatment in COVID-19: A single center experience. - PubMed - NCBI https://t.co/LueYXuXEz6
Antibody to interleukin 6 is possible treatment of #covid19 #ARDS We need to keep looking for as many new treatment possibilities to this #pandemic its funny how the #TrumpSupporters are only obsessed with that old arthritis drug #hydroxychloroquine https://t.co/HQD4YxfzEV
この論文見てると、トシリズマブで解決はするわけではないかなと。 さっきのリツイを考慮すると、高血圧がハイリスクなのは確かにと思ってしまうね。 https://t.co/f24ZCJ2cYR
RT @tango_ballet: COVIDに対するトシリズマブ(= TCZ =アクテムラ)のことを集中的に調べています. 本論文は ・計15例 (中等症2, 重症6, 重篤 7) ・8例はmPSLも併用 ・inclusionと同時に投与開始 ・5例でTCZ 2回以上投与…
RT @julienpotet: Another small cohort study of #tocilizumab (TCZ) for #COVID19 (n=15). Results look favourable, but no control group. Aut…
RT @NeilFlochMD: Several other reports that the effectiveness of this drug is best as the cytokines storm begins with increasing oxygen req…
RT @NeilFlochMD: Several other reports that the effectiveness of this drug is best as the cytokines storm begins with increasing oxygen req…
RT @NeilFlochMD: Several other reports that the effectiveness of this drug is best as the cytokines storm begins with increasing oxygen req…
RT @NeilFlochMD: Several other reports that the effectiveness of this drug is best as the cytokines storm begins with increasing oxygen req…
Several other reports that the effectiveness of this drug is best as the cytokines storm begins with increasing oxygen requirements -#Tocilizumab treatment in COVID‐19: A single center experience - Luo - - Journal of Medical Virology - Wiley Online Library https://t.co/6qTK3UQ9qA
RT @tango_ballet: COVIDに対するトシリズマブ(= TCZ =アクテムラ)のことを集中的に調べています. 本論文は ・計15例 (中等症2, 重症6, 重篤 7) ・8例はmPSLも併用 ・inclusionと同時に投与開始 ・5例でTCZ 2回以上投与…
RT @florindanpopesq: IL-6 is one of the most important #cytokines involved in COVID-19-induced #CytokineStorm [Luo P et al. J Med Virol. 20…
RT @florindanpopesq: #Tocilizumab, humanized monoclonal antibody against IL-6 receptor, appears to be effective treatment option in COVID-1…
RT @florindanpopesq: #Tocilizumab, humanized monoclonal antibody against IL-6 receptor, appears to be effective treatment option in COVID-1…
RT @julienpotet: Another small cohort study of #tocilizumab (TCZ) for #COVID19 (n=15). Results look favourable, but no control group. Aut…
COVIDに対するトシリズマブ(= TCZ =アクテムラ)のことを集中的に調べています. 本論文は ・計15例 (中等症2, 重症6, 重篤 7) ・8例はmPSLも併用 ・inclusionと同時に投与開始 ・5例でTCZ 2回以上投与 ・10例は臨床的に改善・安定 https://t.co/sKyin8QIvp
RT @julienpotet: Another small cohort study of #tocilizumab (TCZ) for #COVID19 (n=15). Results look favourable, but no control group. Aut…
Another small cohort study of #tocilizumab (TCZ) for #COVID19 (n=15). Results look favourable, but no control group. Authors recommend repeated dose for critically ill patients with elevated IL‐6. https://t.co/LyAV3X85f1
#Tocilizumab, humanized monoclonal antibody against IL-6 receptor, appears to be effective treatment option in COVID-19 patients w/ risk of #CytokineStorm. For critically ill patients w/ elevated IL-6, a repeated dose may be recommended [Luo P et al. 2020] https://t.co/2IAceBu3oo
IL-6 is one of the most important #cytokines involved in COVID-19-induced #CytokineStorm [Luo P et al. J Med Virol. 2020] https://t.co/2IAceBu3oo
RT @kelechevarria: Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tel…
RT @kelechevarria: Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tel…
RT @TxID_Edu: Tocilizumab treatment in #COVID19: a single center experience 15 patients - 13 very ill - 8/15 received steroids too - infl…
RT @TxID_Edu: Tocilizumab treatment in #COVID19: a single center experience 15 patients - 13 very ill - 8/15 received steroids too - infl…
RT @TxID_Edu: Tocilizumab treatment in #COVID19: a single center experience 15 patients - 13 very ill - 8/15 received steroids too - infl…
RT @TxID_Edu: Tocilizumab treatment in #COVID19: a single center experience 15 patients - 13 very ill - 8/15 received steroids too - infl…
RT @kelechevarria: Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tel…
Tocilizumab treatment in #COVID19: a single center experience 15 patients - 13 very ill - 8/15 received steroids too - inflammatory markers improved - some got single dose Toci It is very hard to interpret this data https://t.co/Q9TxREryK8 https://t.co/GC5onap1pN
RT @kelechevarria: Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tel…
RT @kelechevarria: Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tel…
RT @ColombianpharmD: Tocilizumab treatment in COVID‐19: a single center experience - Luo - - Journal of Medical Virology - Wiley Online Lib…
RT @kelechevarria: Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tel…
RT @kelechevarria: Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tel…
RT @kelechevarria: Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tel…
RT @ColombianpharmD: Tocilizumab treatment in COVID‐19: a single center experience - Luo - - Journal of Medical Virology - Wiley Online Lib…
RT @kelechevarria: Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tel…
Tocilizumab treatment in COVID‐19: a single center experience - Luo - - Journal of Medical Virology - Wiley Online Library https://t.co/5T3wlnEEBp
RT @kelechevarria: Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tel…
RT @kelechevarria: Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tel…
RT @kelechevarria: Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tel…
RT @kelechevarria: Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tel…
Tocilizumab treatment in COVID‐19: a single center experience https://t.co/npa7FvfS7O
RT @kelechevarria: Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tel…
RT @kelechevarria: Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tel…
Tocilizumab treatment in COVID‐19: a single center experience https://t.co/Y1UcpmQz57 OK my really smart ID friends- tell me what you make of this... It seems at least as good as the non-peer reviewed abstract that got us all jumping off the IL-6 cliff...
I don't agree with the author's conclusions that this case series demonstrated the effectiveness of toci
RT @drsubramanians: #tocilizumab is being tried in critically ill patients with #covid_19 15 patients with severe #covid19 & ⬆️ #IL6 lev…
#tocilizumab is being tried in critically ill patients with #covid_19 15 patients with severe #covid19 & ⬆️ #IL6 levels (2X - 90X normal) 10 of 15 improved 3 of 4 that received only single dose died https://t.co/NGdCTrIoGK #covidclinicalpearls /42
10.1002/jmv.25801 (2020). Crossref · Web of Science · Google Scholar. a [...] higher levels of many of these proteins; b [...] of IL-1β in several patients with ...
Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020; 92: 814–818, DOI: 10.1002/jmv.25801. 14. Li Q, Guan X, Wu ...
Tocilizumab treatment in COVID-19: a single center experience. J Med Virol 2020; 92: 814–818, DOI: 10.1002/jmv.25801. 14. Li Q, Guan X ...
2020;doi:10.1002/jmv.25801. Monteagudo LA, et al. ACR Open Rheumatol. 2020;doi:10.1002/acr2.11135. Muskardin TLW. ACR Open Rheumatol ...
... 10.1002/jmv.25801 7. Di Giambenedetto S, Ciccullo A, Borghetti A, et al. Off‐label Use of Tocilizumab in Patients with SARS‐CoV‐2 Infection ...
KE
SN
NM
CM
JP
C
FF
WF
MR
ZT
CG
RC
A
健
J野
ニ
DK
DM
CS
N
JP
DA
へ
VC
AS
IK
AS
SM
M納
JS
DS
呼
FD
WK
武
MP
JB
I
أم
B
R
RC
WP
J
BP
EL
Aا
ME
AA
BB
AT
V
RC
JA
JK
AB
BF
S
MA